MARCHESELLI, Raffaella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.379
EU - Europa 2.995
AS - Asia 2.568
SA - Sud America 373
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 82
OC - Oceania 15
Totale 13.495
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.179
GB - Regno Unito 1.312
SG - Singapore 760
CN - Cina 692
IT - Italia 482
HK - Hong Kong 306
BR - Brasile 266
VN - Vietnam 254
DE - Germania 253
SE - Svezia 224
FR - Francia 153
FI - Finlandia 127
RU - Federazione Russa 122
CA - Canada 110
BD - Bangladesh 109
UA - Ucraina 109
IN - India 83
TR - Turchia 75
KR - Corea 53
BG - Bulgaria 43
AR - Argentina 42
ID - Indonesia 40
MA - Marocco 40
IQ - Iraq 30
MX - Messico 25
ES - Italia 22
PL - Polonia 22
BE - Belgio 20
NL - Olanda 19
JP - Giappone 18
PK - Pakistan 17
AE - Emirati Arabi Uniti 16
EC - Ecuador 16
CO - Colombia 15
IE - Irlanda 15
SA - Arabia Saudita 15
ZA - Sudafrica 15
AU - Australia 13
CH - Svizzera 13
CZ - Repubblica Ceca 13
CR - Costa Rica 12
MY - Malesia 12
UZ - Uzbekistan 10
VE - Venezuela 10
AT - Austria 9
IR - Iran 9
AZ - Azerbaigian 8
CL - Cile 8
JM - Giamaica 8
LT - Lituania 8
PH - Filippine 8
TT - Trinidad e Tobago 8
DO - Repubblica Dominicana 7
HU - Ungheria 7
JO - Giordania 7
GP - Guadalupe 6
PY - Paraguay 6
BZ - Belize 5
IL - Israele 5
KE - Kenya 5
KG - Kirghizistan 5
KZ - Kazakistan 5
TH - Thailandia 5
DK - Danimarca 4
GT - Guatemala 4
HN - Honduras 4
PR - Porto Rico 4
TN - Tunisia 4
BO - Bolivia 3
CW - ???statistics.table.value.countryCode.CW??? 3
EG - Egitto 3
EU - Europa 3
LB - Libano 3
NO - Norvegia 3
NP - Nepal 3
PE - Perù 3
PS - Palestinian Territory 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
CY - Cipro 2
ET - Etiopia 2
KH - Cambogia 2
MU - Mauritius 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TZ - Tanzania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AO - Angola 1
BB - Barbados 1
Totale 13.400
Salva come PNG Salva come JPEG
Città #
Ashburn 1.205
Southend 1.070
Fairfield 592
Santa Clara 557
Singapore 492
Woodbridge 458
Hong Kong 299
Houston 281
San Jose 272
Chandler 269
Seattle 254
Wilmington 225
Ann Arbor 206
Cambridge 205
Jacksonville 203
Beijing 194
Council Bluffs 185
Dearborn 163
Nyköping 162
Hefei 138
New York 126
London 115
Modena 98
Los Angeles 94
Chicago 90
Milan 90
Helsinki 78
Ho Chi Minh City 70
Frankfurt am Main 66
The Dalles 63
San Diego 59
Hanoi 52
Seoul 50
Buffalo 48
Princeton 44
Shanghai 44
Sofia 42
São Paulo 42
Munich 41
Eugene 38
Toronto 37
Moscow 36
Columbus 35
Salt Lake City 35
Casablanca 32
Lauterbourg 32
Izmir 30
Bologna 26
Bremen 26
Dallas 24
Jakarta 24
Montreal 22
Phoenix 21
Rome 21
Brussels 19
Elk Grove Village 19
Denver 18
Warsaw 18
Boardman 17
Da Nang 17
Redwood City 17
Falls Church 16
Orem 16
Tokyo 16
Brooklyn 15
Turku 15
Des Moines 14
Dublin 14
New Delhi 14
Paris 14
Tampa 14
Nanjing 13
Fremont 12
Guangzhou 12
Manchester 12
Washington 12
Atlanta 11
Baghdad 11
Boston 11
North Bergen 11
Poplar 11
Buenos Aires 10
Chennai 10
Dong Ket 10
San Francisco 10
San José 10
Kunming 9
Naples 9
Newark 9
Norwalk 9
Ottawa 9
Rho 9
Stockholm 9
Dhaka 8
Gurugram 8
Indiana 8
Jeddah 8
Mumbai 8
Philadelphia 8
San Giuliano Milanese 8
Totale 9.739
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 639
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 556
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 481
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 423
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 414
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 409
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy 402
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 377
A concise review of lenalidomide therapy for follicular lymphoma 368
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 354
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 354
Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only 352
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 351
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 350
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 346
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 339
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 338
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 333
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 333
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 328
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 325
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 325
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 320
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 312
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 311
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 308
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 308
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 302
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 299
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 296
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 292
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 289
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 281
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 275
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 246
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 244
Epidemiologia degli infortuni lavorativi in minori: risultati di una indagine condotta nella città di Modena nel periodo gennaio-giugno 2000. 239
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 236
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 235
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 205
Totale 13.495
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.244
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022629 0 0 0 0 24 74 49 50 107 61 156 108
2022/2023854 92 111 60 78 98 118 26 87 93 10 55 26
2023/2024683 24 26 49 63 145 59 146 48 17 16 35 55
2024/20251.761 66 19 42 121 373 276 124 108 195 56 140 241
2025/20263.523 241 144 204 385 586 222 446 171 369 368 212 175
2026/20271.435 102 208 341 642 142 0 0 0 0 0 0 0
Totale 13.495